Prognostic benefit of POLE exonuclease domain mutations in endometrial cancer cannot be explained by increased sensitivity to adjuvant treatment strategies

Prognostic benefit of POLE exonuclease domain mutations in endometrial cancer cannot be explained by increased sensitivity to adjuvant treatment strategies

Bibliographic Details
Main Authors: Van Gool, I, Rayner, E, Osse, E, Tomlinson, I, Smit, V, Creutzberg, C, Church, D, de Wind, N, Bosse, T, Drost, M
Format: Conference item
Published: Wolters Kluwer 2017

Similar Items